{
  "context": {
    "rules": [
      "Rule1: If the drug is effective, then it is not safe for the public.",
      "Rule2: Whenever the organization is banned, the drug is recalled.",
      "Rule3: Provided that the drug is available on the market, it is not profitable.",
      "Rule4: Under the condition that the organization is fined, it is investigated.",
      "Rule5: Either the organization is fined or it is sanctioned.",
      "Rule6: If the organization is sanctioned, then whenever it is not the case that if the research is not ethical then the drug is available on the market, the drug is not restricted.",
      "Rule7: Either the platform is compliant with regulation, or if the research is not ethical then the financial product is not approved on the platform.",
      "Rule8: Whenever the platform is licensed, it is legitimate.",
      "Rule9: Either the platform is operating legally or it is certified.",
      "Rule10: If the platform is certified, then it is not licensed.",
      "Rule11: Either the platform is compliant with the FDA or it is accredited.",
      "Rule12: If the platform is accredited, then whenever it is operating legally, it is not licensed.",
      "Rule13: Whenever the platform is monitored, if it is not the case that if the platform is compliant with the FDA then whenever it is operating legally it is not licensed, then the platform is suspended.",
      "Rule14: Whenever the clinical trial is transparent, if the drug is tested in the clinical trial then the drug is safe.",
      "Rule15: Provided that the review is independent, the results are not biased.",
      "Rule16: If the methodology is rigorous, then whenever the results are replicated, they are verified.",
      "Rule17: Provided that the drug is patented, it is not approved by the FDA.",
      "Rule18: If the drug is generic, then it is not approved by the FDA.",
      "Rule19: Under the condition that the compound is novel, the drug is patented.",
      "Rule20: Whenever the compound is existing, the drug is generic.",
      "Rule21: Either the drug is expensive, or the compound is novel or existing.",
      "Rule22: Whenever the drug has safety issues, it has side effects.",
      "Rule23: Either the drug has safety issues or it has efficacy issues.",
      "Rule24: If the drug is safe, then the platform is not compliant with regulation.",
      "Rule25: Under the condition that the drug has efficacy issues, if the drug is withdrawn then it is recalled.",
      "Rule26: Whenever the drug has side effects, if the drug is withdrawn then it is recalled.",
      "Rule27: Under the condition that the financial product has high demand, if it is successful then it is profitable.",
      "Rule28: Either the financial product has high demand or it is popular.",
      "Rule29: Whenever the financial product is popular, if it is successful then it is profitable.",
      "Rule30: Provided that the drug has a proper dosage, if the drug is compliant with protocol then whenever it is approved by the FDA, it is effective.",
      "Rule31: Either the drug has a proper dosage or it has correct administration.",
      "Rule32: If the organization has trained personnel, then whenever the drug has correct administration, if the drug is compliant with protocol then provided that the drug is approved by the FDA, it is effective.",
      "Rule33: Either the organization has trained personnel or it has qualified staff.",
      "Rule34: If the drug is controversial, then it is accepted.",
      "Rule35: Under the condition that the market is regulated, either the drug is on the black market or if it is not the case that if the research is not ethical then the drug is available on the market, then the drug has limited availability.",
      "Rule36: Whenever the drug is accessible to patients, it is not affordable.",
      "Rule37: Either the drug is accessible to patients, or the drug does not have illegal distribution.",
      "Rule38: Either the drug is subsidized, or if the drug is accessible to patients then it is affordable.",
      "Rule39: Provided that the drug has controlled distribution, it is not subsidized.",
      "Rule40: Either the drug requires a prescription, or if the research is not ethical then the drug is available on the market.",
      "Rule41: Either the drug is over the counter, or the drug does not require a prescription.",
      "Rule42: If the drug is experimental, then it is available on the market.",
      "Rule43: Under the condition that the drug has approved research, either the drug is for research use or if the research is not ethical then the drug is experimental.",
      "Rule44: Provided that the drug has conditional approval, either the drug is for research use or if the research is not ethical then the drug is experimental.",
      "Rule45: If the clinical trial is valid, then the research is ethical.",
      "Rule46: Whenever the drug is in a phase 3 trial, it has approved research.",
      "Rule47: Either the drug is in a phase 3 trial or it is in a phase 4 trial.",
      "Rule48: If the drug is in a phase 4 trial, then it has conditional approval.",
      "Rule49: Provided that the platform is unlicensed, it is not legitimate.",
      "Rule50: Either the platform is unlicensed or it is uncertified.",
      "Rule51: Whenever the platform software is updated, the platform is secure.",
      "Rule52: Either the platform is vulnerable, or if the platform is secure then it is compliant with standards.",
      "Rule53: If the publication is peer-reviewed, then the clinical trial is valid.",
      "Rule54: Under the condition that a warning is issued to the platform, if it is not the case that if the platform is compliant with the FDA then whenever it is operating legally it is not licensed, then the platform is not shutdown.",
      "Rule55: Either a warning is issued to the platform or a violation is found on the platform.",
      "Rule56: If a penalty is imposed on the platform, then whenever it is not the case that if the platform is compliant with the FDA then if it is operating legally it is not licensed, the platform is not shutdown.",
      "Rule57: Under the condition that the platform has a minor violation, if a violation is found on the platform then a penalty is imposed on the platform.",
      "Rule58: Either the platform has a minor violation or it has a major violation.",
      "Rule59: Either a hearing is scheduled for the platform, or if it is not the case that if the platform has a permanent ban then it does not have a temporary suspension, then an appeal is filed for the platform.",
      "Rule60: If the drug is approved by the FDA, then it is safe for the public.",
      "Rule61: Either the drug is approved by the FDA or the publication is peer-reviewed.",
      "Rule62: Provided that it is not the case that if the platform is compliant with the FDA then if it is operating legally it is not licensed, the platform is shutdown.",
      "Rule63: Whenever it is not the case that under the condition that the platform is compliant with the FDA, if it is operating legally then it is not licensed, the platform is not suspended.",
      "Rule64: Under the condition that it is not the case that if the drug is dangerous then it is recalled, the organization faces a lawsuit.",
      "Rule65: Whenever it is not the case that if the drug is dangerous then it is recalled, the organization does not face a lawsuit.",
      "Rule66: Provided that it is not the case that if results are published in a publication then whenever the drug is tested in a clinical trial the drug is safe, the publication is fraudulent.",
      "Rule67: If it is not the case that if the organization has qualified staff then whenever the drug has correct administration, if the drug is compliant with protocol then under the condition that the drug is approved by the FDA it is effective, then the drug is controversial.",
      "Rule68: Under the condition that it is not the case that if the drug is controversial then it is not accepted, the drug is debated.",
      "Rule69: Whenever it is not the case that if the drug is controversial then it is not accepted, the drug is not debated.",
      "Rule70: If it is not the case that if the platform is audited then provided that it is uncertified it is not legitimate, then the platform software is updated.",
      "Rule71: Under the condition that it is not the case that whenever the platform is audited, if it is uncertified then it is not legitimate, the platform is not compliant with standards.",
      "Rule72: Whenever it is not the case that if the platform has a major violation then whenever a violation is found on the platform a penalty is imposed on the platform, the platform has a temporary suspension.",
      "Rule73: Provided that it is not the case that if the platform has a major violation then if a violation is found on the platform a penalty is imposed on the platform, the platform has a permanent ban.",
      "Rule74: Provided that it is not the case that if the drug is approved by the FDA then it is effective, the organization is banned.",
      "Rule75: If it is not the case that under the condition that the drug is approved by the FDA, it is effective, then the drug is withdrawn.",
      "Rule76: Whenever it is not the case that if the drug is approved by the FDA then it is effective, the drug is dangerous.",
      "Rule77: Provided that it is not the case that if the drug is approved by the FDA then it is not safe for the public, the financial product is successful.",
      "Rule78: If it is not the case that whenever the drug is approved by the FDA it is not safe for the public, then the financial product is not profitable.",
      "Rule79: Provided that it is not the case that if the research is not ethical then the drug is available on the market, the drug is restricted.",
      "Rule80: If the clinical trial is not transparent, then the results are biased.",
      "Rule81: Provided that the review is not independent, the results are replicated.",
      "Rule82: Whenever the market is not regulated, the drug has illegal distribution.",
      "Rule83: If the research is not ethical, then the financial product is approved on the platform.",
      "Rule84: Under the condition that the research is not ethical, the drug is profitable.",
      "Rule85: Whenever the research is not ethical, the platform is licensed."
    ],
    "facts": [
      "Fact1: The platform is monitored.",
      "Fact2: The drug is tested in a clinical trial.",
      "Fact3: The methodology is rigorous.",
      "Fact4: The drug is compliant with protocol.",
      "Fact5: Results are published in a publication.",
      "Fact6: The drug has controlled distribution.",
      "Fact7: The platform is audited.",
      "Fact8: It is not the case that the drug is recalled.",
      "Fact9: It is not the case that the organization is investigated.",
      "Fact10: It is not the case that the results are verified.",
      "Fact11: It is not the case that the drug is expensive.",
      "Fact12: It is not the case that the drug has limited availability.",
      "Fact13: It is not the case that the drug is on the black market.",
      "Fact14: It is not the case that the publication is fraudulent.",
      "Fact15: It is not the case that the drug is over the counter.",
      "Fact16: It is not the case that the drug is for research use.",
      "Fact17: It is not the case that the platform is vulnerable.",
      "Fact18: It is not the case that an appeal is filed for the platform.",
      "Fact19: It is not the case that a hearing is scheduled for the platform."
    ]
  },
  "question": "The research is ethical."
}